Home > Signaling Pathways>Protein Tyrosine Kinase>FGFR>JNJ-42756493 (Erdafitinib)
JNJ-42756493 (Erdafitinib)

This product is for research use only, not for human use. We do not sell to patients.

JNJ-42756493 (Erdafitinib)
For small sizes, please check our retail website as below: www.invivochem.com
Size Price Stock
250mg$500In Stock
500mg$850In Stock
1g$1275In Stock

Cat #: V2672 CAS #: 1346242-81-6 Purity ≥ 98%

Description: Erdafitinib (formerly known as JNJ-42756493; JNJ42756493; Balversa), a quinoxaline derivative compound and approved anticancer drug, is a novel, potent and selective, orally bioavailable, pan inhibitor of fibroblast growth factor receptor (FGFR) with potential antineoplastic activity.

References: Perera TP, et al. Discovery and pharmacological characterization of JNJ-42756493 (erdafitinib), a functionally selective small molecule FGFR family inhibitor. Mol Cancer Ther. 2017 Mar 24. pii: molcanther.0589.2016.

Top Publications Citing Invivochem Products
Publications Citing InvivoChem Products

Product Promise

Promise
Molecular Weight (MW)446.54
Molecular FormulaC25H30N6O2
CAS No.1346242-81-6
Storage-20℃ for 3 years in powder formr
-80℃ for 2 years in solvent
Solubility In VitroDMSO: 89 mg/mL (199.3 mM)r
Water: <1 mg/mLr
Ethanol: 89 mg/mL (199.3 mM)
SMILES CodeCC(NCCN(C1=CC(OC)=CC(OC)=C1)C2=CC=C3N=CC(C4=CN(C)N=C4)=NC3=C2)C
SynonymsJNJ 42756493; JNJ-42756493; JNJ42756493
ProtocolIn VitroErdafitinib (JNJ-42756493) inhibits the tyrosine kinase activities of FGFR1-4 in time-resolved fluorescence assays with IC50 values of 1.2, 2.5, 3.0 and 5.7 nM, respectively. The closely related VEGFR2 kinase is less potently inhibited (30-fold less potent compared to FGFR1) by erdafitinib, with an IC50 value of 36.8 nM. Erdafitinib binds FGFR1, 3, 4, and 2 with Kd values of 0.24, 1.1, 1.4 and 2.2 nM, respectively. The Kd value for VEGFR2 is higher at 6.6 nM. Erdafitinib inhibits proliferation of FGFR1, 3, and 4 expressing cells with IC50 values of 22.1, 13.2, and 25nM, respectively.
In VivoIn xenografts from human tumor cell lines or patient-derived tumor tissue with activating FGFR alterations, Erdafitinib administration results in potent and dose-dependent antitumor activity accompanied by pharmacodynamic modulation of phospho-FGFR and phospho-ERK in tumors.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Preparing Stock Solutions
Solvent volume to be added Mass (the weight of a compound)
Mother liquor concentration 1mg5mg10mg20mg
1mM2.2394 mL11.1972 mL22.3944 mL44.7888 mL
5mM0.4479 mL2.2394 mL4.4789 mL8.9578 mL
10mM0.2239 mL1.1197 mL2.2394 mL4.4789 mL
20mM0.1120 mL0.5599 mL1.1197 mL2.2394 mL
Quality Control Documentation
The molarity calculator equation
Mass(g) = Concentration(mol/L) × Volume(L) × Molecular Weight(g/mol)
Mass
=
Concentration
×
Volume
×
Molecular Weight*
The dilution calculator equation
Concentration(start) × Volume(start) = Concentration(final) × Volume(final)

This equation is commonly abbreviated as: C1 V1 = C2 V2

Concentration(start)
C1
×
Volume(start)
V1
=
Concentration(final)
C2
×
Volume(final)
V2
Step One: Enter information below
Dosage mg/kg Average weight of animals g Dosing volume per animal µL Number of animals
Step Two: Enter the in vivo formulation
%DMSO + % + %Tween 80 + %ddH2O

Calculation Results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in µL DMSO(Master liquid concentration mg/mL) ,Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation: Take µL DMSO master liquid, next add µL PEG300, mix and clarify, next add µL Tween 80,mix and clarify, next add µL ddH2O,mix and clarify.
Note:
  • (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
  • (2) Be sure to add the solvent(s) in order.